Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Xuewei Bai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8015-5464; OpenAlex author ID A5065343633. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 3 papers

Papers 12

  1. Corrigendum to "Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma" [Cancer Lett. 449 (2019) … First author DOI 10.1016/j.canlet.2025.218118↗
  2. Corrigendum to "Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis" [Cancer Lett. 481 (2020) 63-75]. Co-author DOI 10.1016/j.canlet.2025.218119↗
  3. RNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement. Co-author DOI 10.1038/s41388-025-03639-y↗
  4. Tumor Cell Derived Lnc-FSD2-31:1 Contributes to Cancer-Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular … Co-author DOI 10.1002/advs.202203324↗
  5. Integrating Genetic and Transcriptomic Data to Reveal Pathogenesis and Prognostic Markers of Pancreatic Adenocarcinoma. Last author DOI 10.3389/fgene.2021.747270↗
  6. Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis. Co-author DOI 10.1016/j.canlet.2020.02.039↗
  7. Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2019.02.006↗
  8. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. Co-author DOI 10.1186/s13045-019-0837-z↗
  9. Recent advances in research on aspartate β-hydroxylase (ASPH) in pancreatic cancer: A brief update. Last author DOI 10.17305/bjbms.2018.3539↗
  10. Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic Cancer Proliferation and Metastasis via the Stimulation of Autophagy. Co-author DOI 10.1158/1535-7163.mct-16-0008↗
  11. Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway. Last author DOI 10.1007/s00280-011-1643-7↗
  12. Nuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions. Last author DOI 10.1371/journal.pone.0023752↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Katsuya Nagaoka · 5 shared papers, 2019–2026 · strength 0.74
  2. Xiaoqun Dong · 5 shared papers, 2019–2026 · strength 0.74
  3. Jack R. Wands · 5 shared papers, 2019–2026 · strength 0.74
  4. Kosuke Ogawa · 5 shared papers, 2019–2026 · strength 0.74
  5. Bei Sun · 7 shared papers, 2011–2026 · strength 0.68
  6. Rui Kong · 6 shared papers, 2011–2026 · strength 0.48
  7. Chundong Cheng · 2 shared papers, 2023–2026 · strength 0.42
  8. Wenbo Yang · 2 shared papers, 2023–2026 · strength 0.42
  9. Hongze Chen · 2 shared papers, 2023–2026 · strength 0.42
  10. Qiushi Lin · 3 shared papers, 2019–2026 · strength 0.38
  11. Lianxin Liu · 3 shared papers, 2019–2026 · strength 0.38
  12. Le Li · 3 shared papers, 2019–2026 · strength 0.38
  13. Howard P. Safran · 3 shared papers, 2019–2026 · strength 0.38
  14. Yongwei Wang · 5 shared papers, 2011–2023 · strength 0.37
  15. Min Li · 2 shared papers, 2019–2026 · strength 0.30
  16. Chengxiao Yang · 1 shared paper, 2026 · strength 0.28
  17. Xinyuan Liu · 1 shared paper, 2026 · strength 0.28
  18. Yongwei Wang · 1 shared paper, 2026 · strength 0.22
  19. Bei Sun · 2 shared papers, 2019–2023 · strength 0.21
  20. Gang Wang · 2 shared papers, 2016–2023 · strength 0.19
  21. Le Li · 2 shared papers, 2016–2023 · strength 0.19
  22. Xinglong Geng · 1 shared paper, 2023 · strength 0.14
  23. Guanqun Li · 1 shared paper, 2023 · strength 0.14
  24. Tao Zhang · 1 shared paper, 2023 · strength 0.14
  25. Zhongjie Zhao · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.